Interactions between glutamate, dopamine, and the neuronal signature of response inhibition in the human striatum

Human Brain Mapping

Volumn 36, Issue 10, 2015, Pages 4031-4040

  Lorenz, Robert C ^a,b,c   Gleich, Tobias ^a   Buchert, Ralph ^a   Schlagenhauf, Florian ^a,d   Kühn, Simone ^c,e   Gallinat, Jürgen ^a,e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c MAX PLANCK INSTITUTE FOR HUMAN DEVELOPMENT   (Germany)

^d MAX PLANCK INSTITUTE FOR HUMAN COGNITIVE AND BRAIN SCIENCES   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Dopamine; Functional magnetic resonance imaging; Glutamate; Magnetic resonance spectroscopy; Multimodal imaging; Positron emission tomography; Response inhibition; Striatum

Indexed keywords

6 FLUORODOPA F 18; DOPAMINE; GLUTAMIC ACID;

ADULT; AGED; ARTICLE; ASSOCIATION; BEHAVIOR CONTROL; BOLD SIGNAL; CAUDATE NUCLEUS; CLINICAL ASSESSMENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DRUG METABOLISM; EVENT RELATED POTENTIAL; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; HUMAN; HUMAN EXPERIMENT; IMAGE PROCESSING; IN VIVO STUDY; INHIBITION (PSYCHOLOGY); MALE; NERVE CELL; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION TIME; RESPONSE INHIBITION; TASK PERFORMANCE; AGING; BRAIN MAPPING; CYTOLOGY; DOPAMINERGIC NERVE CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSIOLOGY; PSYCHOMOTOR PERFORMANCE; SCINTISCANNING;

ADULT; AGING; BRAIN MAPPING; CAUDATE NUCLEUS; CORPUS STRIATUM; DOPAMINE; DOPAMINERGIC NEURONS; FEMALE; GLUTAMIC ACID; HUMANS; INHIBITION (PSYCHOLOGY); MAGNETIC RESONANCE IMAGING; MALE; NEURONS; POSITRON-EMISSION TOMOGRAPHY; PSYCHOMOTOR PERFORMANCE; REACTION TIME;

EID: 84942278806     PISSN: 10659471     EISSN: 10970193     Source Type: Journal    
DOI: 10.1002/hbm.22895     Document Type: Article

References (57)

1. Aalto S, Hirvonen J, Kajander J, Scheinin H, Någren K, Vilkman H, Gustafsson L, Syvälahti E, Hietala J (2002): Ketamine does not decrease striatal dopamine D2 receptor binding in man. Psychopharmacology (Berl) 164:401-406.
2. Bari A, Robbins TW (2013): Inhibition and impulsivity: Behavioral and neural basis of response control. Prog Neurobiol 108:44-79.
3. Bloemen OJ, Gleich T, de Koning MB, da Silva Alvis F, de Haan L, Linszen DH, Booij J, van Amelsvoort TA (2011): Hippocampal glutamate levels and striatal dopamine D(2/3) receptor occupancy in subjects at ultra high risk of psychosis. Biol Psychiatry 70:e1-2.
4. Braskie MN, Wilcox CE, Landau SM, O'Neil JP, Baker SL, Madison CM, Kluth JT, Jagust WJ (2008): Relationship of striatal dopamine synthesis capacity to age and cognition. J Neurosci 28:14320-14328.
5. Breier A, Adler CM, Weisenfeld N, Su TP, Elman I, Picken L, Malhotra AK, Pickar D (1998): Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 29:142-147.
6. Buckholtz JW, Treadway MT, Cowan RL, Woodward ND, Li R, Ansari MS, Baldwin RM, Schwartzman AN, Shelby ES, Smith CE, Kessler RM, Zald DH (2010): Dopaminergic network differences in human impulsivity. Science 329:532.
7. Carlsson A, Waters N, Carlsson ML (1999): Neurotransmitter interactions in schizophrenia-therapeutic implications. Biol Psychiatry 46:1388-1395.
8. Chambers CD, Garavan H, Bellgrove MA (2009): Insights into the neural basis of response inhibition from cognitive and clinical neuroscience. Neurosci Biobehav Rev 33:631-646.
9. Cools R, D'Esposito M (2011): Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol Psychiatry 69:e113-125.
10. Cools R, Gibbs SE, Miyakawa A, Jagust W, D'Esposito M (2008): Working memory capacity predicts dopamine synthesis capacity in the human striatum. J Neurosci 28:1208-1212.
11. Cropley VL, Fujita M, Innis RB, Nathan PJ (2006): Molecular imaging of the dopaminergic system and its association with human cognitive function. Biol Psychiatry 59:898-907.
12. Dalley JW, Fryer TD, Brichard L, Robinson ESJ, Theobald DEH, Laane K, Pena Y, Murphy ER, Shah Y, Probst K, Abakumova I, Aigbirhio FI, Richards HK, Hong Y, Baron JC, Everitt BJ, Robbins TW (2007): Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science 315:1267-1270.
13. De la Fuente-Sandoval C, León-Ortiz P, Favila R, Stephano S, Mamo D, Ramírez-Bermúdez J, Graff-Guerrero A (2011): Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology 36:1781-1791.
14. De la Fuente-Sandoval C, León-Ortiz P, Azcárraga M, Favila R, Stephano S, Graff-Guerrero A (2013): Striatal glutamate and the conversion to psychosis: a prospective 1H-MRS imaging study. Int J Neuropsychopharmacol 16:471-475.
15. De Wit H, Enggasser JL, Richards JB (2002): Acute administration of d-amphetamine decreases impulsivity in healthy volunteers. Neuropsychopharmacology 27:813-825.
16. Enticott PG, Ogloff JR, Bradshaw JL (2008): Response inhibition and impulsivity in schizophrenia. Psychiatry Res 157:251-254.
17. 3 receptors mediate response inhibition and related activity in frontostriatal neural circuitry in humans. J Neurosci off J Soc Neurosci 32:7316-7324.
18. Gleich T, Lorenz RC, Pöhland L, Raufelder D, Deserno L, Beck A, Heinz A, Kühn S, Gallinat J (2014): Frontal glutamate and reward processing in adolescence and adulthood. Brain Struct Funct. Advance online publication.
19. Hamidovic A, Dlugos A, Skol A, Palmer AA, de Wit H (2009): Evaluation of genetic variability in the dopamine receptor D2 in relation to behavioral inhibition and impulsivity/sensation seeking: an exploratory study with d-amphetamine in healthy participants. Exp Clin Psychopharmacol 17:374-383.
20. Hietala J, Syvälahti E, Vuorio K, Räkköläinen V, Bergman J, Haaparanta M, Solin O, Kuoppamäki M, Kirvelä O, Ruotsalainen U (1995): Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 346:1130-1131.
21. Hoaglin DC, Iglewicz B, Tukey JW (1986): Performance of some resistant rules for outlier labeling. J Am Stat Assoc 81:991-999.
22. Howes OD, Kapur S (2009): The dopamine hypothesis of schizophrenia: version III-The final common pathway. Schizophr Bull 35:549-562.
23. Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, Kapur S (2012): The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 69:776-786.
24. Ito H, Kodaka F, Takahashi H, Takano H, Arakawa R, Shimada H, Suhara T (2011): Relation between presynaptic and postsynaptic dopaminergic functions measured by positron emission tomography: Implication of dopaminergic tone. J Neurosci 31:7886-7890.
25. Kandel ER, Schwartz JH, Jessell TM (2000): Principles of Neural Science Auflage, 4th Revised ed. New York: Mcgraw-Hill Professional.
26. Kegeles LS, Martinez D, Kochan LD, Hwang D-R, Huang Y, Mawlawi O, Suckow RF, Van Heertum RL, Laruelle M (2002): NMDA antagonist effects on striatal dopamine release: positron emission tomography studies in humans. Synapse 43:19-29.
27. Koob GF, Volkow ND (2010): Neurocircuitry of addiction. Neuropsychopharmacology 35:217-238.
28. Kumakura Y, Cumming P (2009): PET Studies of Cerebral Levodopa Metabolism: A Review of Clinical Findings and Modeling Approaches. Neuroscientist. 15:635-650.
29. Kumakura Y, Vernaleken I, Buchholz H-G, Borghammer P, Danielsen E, Gründer G, Heinz A, Bartenstein P, Cumming P (2010): Age-dependent decline of steady state dopamine storage capacity of human brain: An FDOPA PET study. Neurobiol Aging 31:447-463.
30. Landau SM, Lal R, O'Neil JP, Baker S, Jagust WJ (2009): Striatal dopamine and working memory. Cereb Cortex 19:445-454.
31. Lawrence AD, Weeks RA, Brooks DJ, Andrews TC, Watkins LH, Harding AE, Robbins TW, Sahakian BJ (1998): The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease. Brain J Neurol 121:1343-1355.
32. Logan GD, Cowan WB (1984): On the ability to inhibit thought and action: A theory of an act of control. Psychol Rev 91:295-327.
33. Logothetis NK, Pauls J, Augath M, Trinath T, Oeltermann A (2001): Neurophysiological investigation of the basis of the fMRI signal. Nature 412:150-157.
34. Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, Weinberger DR, Berman KF (2002): Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 5:267-271.
35. Mora F, Segovia G, del Arco A (2008): Glutamate-dopamine-GABA interactions in the aging basal ganglia. Brain Res Rev 58:340-353.
36. Morales I, Fuentes A, Ballaz S, Obeso JA, Rodriguez M (2012): Striatal interaction among dopamine, glutamate and ascorbate. Neuropharmacology 63:1308-1314.
37. Nair AG, Gutierrez-Arenas O, Eriksson O, Jauhiainen A, Blackwell KT, Kotaleski JH (2014): Modeling intracellular signaling underlying striatal function in health and disease. Prog Mol Biol Transl Sci 123:277-304.
38. Nozaki S, Kato M, Takano H, Ito H, Takahashi H, Arakawa R, Okumura M, Fujimura Y, Matsumoto R, Ota M, Takano A, Otsuka A, Yasuno F, Okubo Y, Kashima H, Suhara T (2009): Regional dopamine synthesis in patients with schizophrenia using L-[β-11C]DOPA PET. Schizophr Res 108:78-84.
39. Preacher KJ, Hayes AF (2008): Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav Res Methods 40:879-891.
40. Provencher SW (1993): Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30:672-679.
41. Ray Li C-S, Yan P, Sinha R, Lee T-W (2008): Subcortical processes of motor response inhibition during a stop signal task. NeuroImage 41:1352-1363.
42. Rothman DL, Sibson NR, Hyder F, Shen J, Behar KL, Shulman RG (1999): In vivo nuclear magnetic resonance spectroscopy studies of the relationship between the glutamate-glutamine neurotransmitter cycle and functional neuroenergetics. Philos Trans R Soc Lond B Biol Sci 354:1165-1177.
43. Schlagenhauf F, Rapp MA, Huys QJ, Beck A, Wüstenberg T, Deserno L, Buchholz H-G, Kalbitzer J, Buchert R, Bauer M, Kienast T, Cumming P, Plotkin M, Kumakura Y, Grace AA, Dolan RJ, Heinz A (2013): Ventral striatal prediction error signaling is associated with dopamine synthesis capacity and fluid intelligence. Hum Brain Mapp 34:1490-1499.
44. Schott BH, Minuzzi L, Krebs RM, Elmenhorst D, Lang M, Winz OH, Seidenbecher CI, Coenen HH, Heinze H-J, Zilles K, Düzel E, Bauer A (2008): Mesolimbic functional magnetic resonance imaging activations during reward anticipation correlate with reward-related ventral striatal dopamine release. J Neurosci off J Soc Neurosci 28:14311-14319.
45. Schwartz TL, Sachdeva S, Stahl SM (2012): Glutamate Neurocircuitry: Theoretical Underpinnings in Schizophrenia. Front Pharmacol 3:195
46. Segovia G, Mora F (2001): Involvement of NMDA and AMPA/kainate receptors in the effects of endogenous glutamate on extracellular concentrations of dopamine and GABA in the nucleus accumbens of the awake rat. Brain Res Bull 54:153-157.
47. Smith GS, Schloesser R, Brodie JD, Dewey SL, Logan J, Vitkun SA, Simkowitz P, Hurley A, Cooper T, Volkow ND, Cancro R (1998): Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects. Neuropsychopharmacology 18:18-25.
48. Swanson JM, Kinsbourne M, Nigg J, Lanphear B, Stefanatos GA, Volkow N, Taylor E, Casey BJ, Castellanos FX, Wadhwa PD (2007): Etiologic subtypes of attention-deficit/hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. Neuropsychol Rev 17:39-59.
49. Tewes U (1991): Hamburg-Wechsler Intelligenztest für Erwachsene - Revision 1991 (HAWIE-R). Bern: Huber.
50. Thoma P, Wiebel B, Daum I (2007): Response inhibition and cognitive flexibility in schizophrenia with and without comorbid substance use disorder. Schizophr Res 92:168-180.
51. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M (2002): Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15:273-289.
52. Verbruggen F, Logan GD (2008): Response inhibition in the stop-signal paradigm. Trends Cogn Sci 12:418-424.
53. Verbruggen F, Logan GD (2009): Models of response inhibition in the stop-signal and stop-change paradigms. Neurosci Biobehav Rev 33:647-661.
54. Vernaleken I, Klomp M, Moeller O, Raptis M, Nagels A, Rösch F, Schaefer WM, Cumming P, Gründer G (2013): Vulnerability to psychotogenic effects of ketamine is associated with elevated D2/3-receptor availability. Int J Neuropsychopharmacol 16:745-754.
55. Vink M, Kahn RS, Raemaekers M, van den Heuvel M, Boersma M, Ramsey NF (2005): Function of striatum beyond inhibition and execution of motor responses. Hum Brain Mapp 25:336-344.
56. Vollenweider FX, Vontobel P, Oye I, Hell D, Leenders KL (2000): Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. J Psychiatr Res 34:35-43.
57. Zahr NM, Mayer D, Pfefferbaum A, Sullivan EV (2008): Low striatal glutamate levels underlie cognitive decline in the elderly: evidence from in vivo molecular spectroscopy. Cereb Cortex 18:2241-2250.